Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Finished Goods (2016 - 2019)

Tandem Diabetes Care (TNDM) has disclosed Finished Goods for 6 consecutive years, with $9.7 million as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Finished Goods fell 21.48% year-over-year to $9.7 million, compared with a TTM value of $9.7 million through Mar 2019, down 21.48%, and an annual FY2018 reading of $10.6 million, down 17.81% over the prior year.
  • Finished Goods was $9.7 million for Q1 2019 at Tandem Diabetes Care, down from $10.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $14.4 million in Q3 2017 and bottomed at $2.9 million in Q2 2015.
  • Average Finished Goods over 5 years is $8.5 million, with a median of $9.1 million recorded in 2016.
  • The sharpest move saw Finished Goods soared 145.5% in 2016, then dropped 21.48% in 2019.
  • Year by year, Finished Goods stood at $3.5 million in 2015, then skyrocketed by 109.57% to $7.4 million in 2016, then surged by 73.1% to $12.9 million in 2017, then dropped by 17.81% to $10.6 million in 2018, then decreased by 8.36% to $9.7 million in 2019.
  • Business Quant data shows Finished Goods for TNDM at $9.7 million in Q1 2019, $10.6 million in Q4 2018, and $11.3 million in Q3 2018.